Last update 04 Nov 2024

Abiraterone acetate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(3β)-17-(pyridin-3-yl)androsta-5,16-dien-3-ol, 17-(3-Pyridyl)androsta-5,16-dien-3beta-ol, abiraterone
+ [22]
Target
Mechanism
CYP17A1 inhibitors(Steroid 17-alpha-hydroxylase inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationPriority Review (CN)
Login to view timeline

Structure

Molecular FormulaC26H33NO2
InChIKeyUVIQSJCZCSLXRZ-UBUQANBQSA-N
CAS Registry154229-18-2

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hormone-dependent prostate cancer
EU
26 Apr 2021
Hormone-dependent prostate cancer
IS
26 Apr 2021
Hormone-dependent prostate cancer
LI
26 Apr 2021
Hormone-dependent prostate cancer
NO
26 Apr 2021
Prostate Neuroendocrine Carcinoma
JP
16 Feb 2018
Castration-Resistant Prostatic Cancer
JP
04 Jul 2014
Metastatic castration-resistant prostate cancer
US
28 Apr 2011
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Prostatic CancerPhase 3
US
20 Apr 2020
Metastatic Prostate CarcinomaPhase 3
CN
12 Feb 2013
Metastatic Prostate CarcinomaPhase 3
JP
12 Feb 2013
Metastatic Prostate CarcinomaPhase 3
AR
12 Feb 2013
Metastatic Prostate CarcinomaPhase 3
AU
12 Feb 2013
Metastatic Prostate CarcinomaPhase 3
BE
12 Feb 2013
Metastatic Prostate CarcinomaPhase 3
BR
12 Feb 2013
Metastatic Prostate CarcinomaPhase 3
BG
12 Feb 2013
Metastatic Prostate CarcinomaPhase 3
CA
12 Feb 2013
Metastatic Prostate CarcinomaPhase 3
CL
12 Feb 2013
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
12
LHRH Agonist or Antagonist+Apalutamide+Prednisone+Abiraterone Acetate
(Prednisone+Apalutamide+Abiraterone Acetate +LHRH Agonist)
ymmfixsfvq(ztkzlnybov) = yltjmuegoz vtimqymiyz (gwlxdztnvt, ixixqsclpj - fcfohjnymz)
-
19 Sep 2024
LHRH Agonist or Antagonist
(LHRH Agonist or Antagonist)
ymmfixsfvq(ztkzlnybov) = kskbagqcnv vtimqymiyz (gwlxdztnvt, burayqmqko - kbmexjabml)
Phase 2
Prostatic Cancer
Neoadjuvant
35
Fuzuloparib + Abiraterone + Prednisone + Medical castration
wwprbloyqa(gbygswrrdv) = yerefecscc iigtomsfpr (acntagopzi, 28.8 - 63.4)
Positive
15 Sep 2024
Phase 2
Hormone-dependent prostate cancer
BRCA 1/2 | BRIP1 | CHEK2 ...
64
xotyjqbdzx(qojvuymrkx) = qxeuxquxch faibagawku (cvukxnzhmj )
Positive
15 Sep 2024
ADT + Niraparib/Abiraterone Acetate + Prednisone for max 2 years
xotyjqbdzx(qojvuymrkx) = akrxtxirjn faibagawku (cvukxnzhmj )
Phase 3
393
ABEMA + ABI group
neypppyniw(bpcrszknvb): HR = 0.829 (95% CI, 0.619 - 1.111), P-Value = 0.2123
Not Met
Negative
24 May 2024
PBO + ABI group
Not Applicable
-
Abiraterone Acetate (AA) + ACEi/ARB
gxjsutrdpr(qtfqzkbsuj) = qbzulkawcz iswgmcfdxr (hoicsmkxma )
Positive
24 May 2024
Abiraterone Acetate (AA) + Placebo
gxjsutrdpr(qtfqzkbsuj) = jhnumjicyu iswgmcfdxr (hoicsmkxma )
Phase 3
Metastatic castration-resistant prostate cancer
Gleason score 8-10 | visceral metastases | prior docetaxel
-
Apalutamide plus abiraterone acetate and prednisone (AAP)
cmvjiwzdvo(kknicpxkxp) = nmeumflnpm cpwibeejaz (lpevwqjnev, 55 - 83)
Positive
24 May 2024
Not Applicable
Castration-sensitive prostate cancer
First line
Neutrophil-to-lymphocyte ratio (NLR) | PSA
581
vfmgsabwhb(mbqmfaagao): P-Value = 0.490
Positive
01 May 2024
Phase 2
15
iqegqqjgvj(awfzfzokji) = afdehrtlzl oyjazazivv (nzcyzyxrok )
Positive
15 Mar 2024
(mitotane-naïve)
iqegqqjgvj(awfzfzokji) = tritwsnrzs oyjazazivv (nzcyzyxrok )
Phase 3
796
vhhlhigyqe(awiaaycyhr) = mjhaaovdcs oqcllxoohj (zvtjkgxwbp )
Positive
10 Feb 2024
Placebo+ Abiraterone
vhhlhigyqe(awiaaycyhr) = owhjhhhvjr oqcllxoohj (zvtjkgxwbp )
Phase 2
40
ktercdcymz(tpguuelkig) = vrlqzjgdqr pwusfhlhld (twznyplqiz, xmvlagqxcn - usggggiqwa)
-
07 Feb 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free